Budesonide novolizer
PreclinicalSmall molecule
Budesonide novolizer is one of 13 small molecule programs targeting Chronic Cough. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Chronic Cough
#DrugCompanyPhaseTrials
1Singulair
OOrganon and Co
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Nucala
GGlaxo Dba Glaxosmithkline
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Quietus
Merck & Co.Phase 3
Pulmicort
SSalix
Preclinical
NOC-110
NNocion Therapeutics
Phase 2
HS-10383
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 2
Iron Sulphate
PPierre Fabre Pharma GmbH
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Cough1 trial
Predictive Factors in Response to Inhaled Corticoids in Chronic Cough
Unknown status·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·N/A·NCT02715167·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Budesonide novolizer. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details